Atlas Trials

iOMEDICO AG

53 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch iOMEDICO AG

RecordFirmDate
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM) (NCT07559799)iOMEDICO AG2026-06-01
Research Platform Myelofibrosis and Anemia (NCT06976918)iOMEDICO AG2026-02-19
Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma (NCT07240662)iOMEDICO AG2025-12-08
Fruquintinib in Patients With Metastatic Colorectal Cancer (NCT06787105)iOMEDICO AG2025-02-17
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly (NCT06743035)iOMEDICO AG2024-12-03
Ripretinib (QINLOCK®) According to Current SmPC (NCT06619275)iOMEDICO AG2024-10-17
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study (NCT06607302)iOMEDICO AG2024-10-08
Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC (NCT06181734)iOMEDICO AG2023-12-20
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms (NCT06043011)iOMEDICO AG2023-09-27
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma (NCT05954780)iOMEDICO AG2023-06-28
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) (NCT05517265)iOMEDICO AG2022-10-12
Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) (NCT05284591)iOMEDICO AG2022-07-06
Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens. (NCT05253911)iOMEDICO AG2022-05-21
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (NCT05326308)iOMEDICO AG2022-04-26
Registry Platform Ovarian and Endometrial Cancer (NCT05129969)iOMEDICO AG2021-11-25
Registry Platform Colorectal Cancer (NCT04867525)iOMEDICO AG2021-05-01
Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion (NCT04557813)iOMEDICO AG2020-12-02
Liver Cancer Registry Platform (NCT04510740)iOMEDICO AG2020-08-09
Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology (NCT04389541)iOMEDICO AG2020-04-17
Registry Platform Gastric/Esophageal Cancer (SAPHIR) (NCT04290806)iOMEDICO AG2019-12-04
Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy (NCT03911219)iOMEDICO AG2019-07-10
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (NCT03811418)iOMEDICO AG2019-01-01
Patient Preference for Pegfilgrastim (Neulasta®) Application Forms (NCT03619993)iOMEDICO AG2018-06-25
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line (NCT03462251)iOMEDICO AG2018-05-24
Breast Cancer Registry Platform (NCT03417115)iOMEDICO AG2017-12-22
Myeloma Registry Platform (MYRIAM) (NCT03308474)iOMEDICO AG2017-09-25

Track iOMEDICO AG automatically

Every clearance here is in the API, with alerts when new ones post.